LGMC Conducting Clinical Trial on Myeloma

4/29/2015

Cancer Center of Acadiana (CCA) at Lafayette General Medical Center is seeking men and women, ages 18 and older, diagnosed with multiple myeloma to participate in a clinical trial.

This research study will compare the effectiveness of a combination of investigational medications in subjects with previously untreated multiple myeloma who are ineligible for high-dose therapy. This is a Phase III clinical trial. Drugs that successfully pass Phase III may be approved for use in the general population by the national regulatory authority.

CCA Oncologist Sal Malad, M.D., is principle investigator of this study, sponsored by Janssen Research & Development, LLC, in cooperation with other CCA oncologists. The investigational drug daratumumab will be evaluated in terms of progression-free survival (PFS) in subjects with newly diagnosed myeloma who are not candidates for high dose chemotherapy and autologous stem cell transplant.

CCA participates in clinical trials and studies to help improve patient care and disease prevention. Clinical trials can offer several benefits, such as access to investigational drugs that might not otherwise be available. Trials also help expand knowledge about the best ways to treat cancer for other in the future.

Clinical trials also empower a patient who may not be responding ideally to treatment to make his or her own decision. Physicians, nurses and other team members at CCA will thoroughly instruct a patient on potential risks and benefits of participating in a clinical trial. The staff will then closely monitor and assess the progress of the trial and continue this through follow-up care.

When patients participate in a clinical trial, they are not only advancing medical technology, they are providing a valuable benefit to future generations. The goal of clinical trials at CCA is to support the patient-centered approach to health care.

For more information on this and other clinical trials available at Lafayette General Medical Center, call (337) 289-8658 or visit our clinical trials for cancer page.

Back to News Listing